NCT04821765 - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2024

Conditions

Esophagus CancerChemoradiotherapyOligometastatic DiseaseImmunotherapy

Interventions

DRUG

PD-1 antibody

200mg, d1, q3W

RADIATION

Chemoradiation

50-60Gy (BED) was given (1.8-2 Gy or 3-4Gy once daily , 5 days a week

DRUG

Albumin-Bound Paclitaxel

150mg/m2, d1, q3W

DRUG

Cisplatin

75mg/m2, d1, q3W

Trial Locations (2)

100021

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

455001

Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER